Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Patient-Focused Drug Development Meetings Inspire Imitators

Executive Summary

FDA likes the idea of advocacy groups convening their own meetings, but some stakeholders say the conversations need more depth.

You may also be interested in...



US FDA Expands Patient Input To New Area: Orphan Grant Applications

Patient experience will be incorporated into agency orphan grant reviews, and outside rare disease experts will help make decisions.

FDA Ends Regularly Scheduled Patient-Focused Drug Development Meetings

After conducting 24 disease-focused meetings in five years, FDA moving to next phase of patient interaction under new user fee cycle.

US FDA Planning Another Patient Group To Boost Involvement

Patient Engagement Collaborative expected to invite stakeholders to discuss how patient interaction with FDA can improve.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS056121

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel